Procept Biorobotics has secured a significant win with the assignment of a Category I CPT code for its Aquablation therapy, effective January 1, 2026. This shift from a Category III code to 52xx1 signifies more than just administrative streamlining; it represents a critical inflection point in the adoption and reimbursement of this novel BPH treatment. The new code solidifies Aquablation’s position within the standard of care, potentially accelerating market penetration and impacting the competitive landscape for BPH surgical interventions.
The financial implications are substantial. The proposed 2026 Medicare Physician Fee Schedule assigns 16.14 total RVUs to the new code, translating to an approximate national average reimbursement of $540. This puts Aquablation on near-equal footing with TURP (15.82 RVUs and approximately $529), a long-standing benchmark procedure. This near-parity in reimbursement, combined with Aquablation’s clinical advantages, could significantly influence surgeon preference and patient access. Payers will be closely scrutinizing the cost-effectiveness data as utilization increases, particularly given the growing prevalence of BPH.
The timing of this code assignment aligns with broader trends in urological surgery. Minimally invasive procedures are gaining traction, driven by patient demand for quicker recovery times and reduced side effects. Aquablation, with its robotic-assisted, heat-free waterjet technology, addresses these demands directly. The technology’s ability to precisely target prostate tissue while preserving critical anatomical structures offers a compelling value proposition to both surgeons and patients, particularly those concerned about sexual function preservation. This development further underscores the increasing importance of robotics and AI in surgical procedures, driving innovation and potentially changing the training landscape for urologists.
Looking ahead, the Category I CPT code is likely to spur increased investment and competition in the BPH treatment space. Other companies developing minimally invasive technologies will need to demonstrate clear clinical and economic differentiation to compete effectively with Aquablation. The focus will likely shift to generating robust real-world evidence (RWE) to further validate long-term outcomes and cost-effectiveness. This will require strategic collaborations between Medical Affairs teams, payers, and data analytics providers. The ability to effectively communicate the value of these innovations to payers and HCPs will be crucial for market success in this increasingly competitive landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
